Ongoing trials of checkpoint inhibitors in sarcoma do not involve selection of patients with genomic biomarkers such as CD274 (PD-L1) amplification or high MSI, TMB, or tumor-infiltrating lymphocytes, but instead are limited to histologic subtypes (e.g. LMS, UPS/MFH, ASPS) in which responses were seen in early clinical trials41,42,47,80. Here, CD274 is linked to neoplasm.